High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B - PubMed

Affiliations

• PMID: 19267406
• DOI: 10.1002/ijc.24281

Comparative Study

High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B

Vincent Wai-Sun Wong et al. Int J Cancer. 2009.

Abstract

Increased interleukin-6 (IL-6) production is implicated in the pathogenesis of hepatocellular carcinoma (HCC) in animal models. Although previous studies showed that HCC patients had higher serum IL-6 level at the time of diagnosis, it is unclear if the cytokine contributes to the development of HCC or is just a reaction to cancer. To address this question, we performed a nested case-control study. Consecutive chronic hepatitis B patients were recruited from 1997 to 2000 and followed till 2008. Profiling of 27 cytokines, chemokines and growth factors was performed at baseline, date of peak alanine aminotransferase (ALT) level and the last visit. Thirty-seven patients developed HCC at a median follow-up of 62 months (interquartile range: 41-110). Serum IL-6 was higher in patients with HCC than controls both during peak ALT and at the last visit (both p = 0.02). Patients with IL-6 above 7 pg/ml during peak ALT had increased risk of HCC or death (adjusted hazard ratio 3.0; 95% confidence interval 1.2, 7.8; p = 0.02). The sensitivity, specificity, positive and negative predictive values of this cutoff to predict future HCC development were 70%, 73%, 72% and 71%, respectively. Combination of IL-6 and AFP improved the sensitivity in diagnosing HCC or predicting future HCC development. In conclusion, high serum IL-6 level predates the development of HCC in chronic hepatitis B patients, and has moderate accuracy in predicting future cancer. This may assist clinicians in selecting high-risk patients for HCC surveillance program.

Similar articles

• Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment.

  Cho HJ, Kim SS, Ahn SJ, Park SY, Park JH, Kim JK, Wang HJ, Cheong JY, Cho SW. Cho HJ, et al. Cytokine. 2015 Jun;73(2):245-52. doi: 10.1016/j.cyto.2015.02.027. Epub 2015 Mar 19. Cytokine. 2015. PMID: 25797190

• Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences.

  Nakagawa H, Maeda S, Yoshida H, Tateishi R, Masuzaki R, Ohki T, Hayakawa Y, Kinoshita H, Yamakado M, Kato N, Shiina S, Omata M. Nakagawa H, et al. Int J Cancer. 2009 Nov 15;125(10):2264-9. doi: 10.1002/ijc.24720. Int J Cancer. 2009. PMID: 19585572

• Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma.

  Chan HL, Hui AY, Wong ML, Tse AM, Hung LC, Wong VW, Sung JJ. Chan HL, et al. Gut. 2004 Oct;53(10):1494-8. doi: 10.1136/gut.2003.033324. Gut. 2004. PMID: 15361502 Free PMC article.

• Natural history of chronic hepatitis B REVEALed.

  Chen CJ, Yang HI. Chen CJ, et al. J Gastroenterol Hepatol. 2011 Apr;26(4):628-38. doi: 10.1111/j.1440-1746.2011.06695.x. J Gastroenterol Hepatol. 2011. PMID: 21323729 Review.

• The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets.

  Ringelhan M, O'Connor T, Protzer U, Heikenwalder M. Ringelhan M, et al. J Pathol. 2015 Jan;235(2):355-67. doi: 10.1002/path.4434. J Pathol. 2015. PMID: 25196558 Review.

Cited by

• Gender difference in the prognostic role of interleukin 6 in oral squamous cell carcinoma.

  Chen CJ, Sung WW, Lin YM, Chen MK, Lee CH, Lee H, Yeh KT, Ko JL. Chen CJ, et al. PLoS One. 2012;7(11):e50104. doi: 10.1371/journal.pone.0050104. Epub 2012 Nov 21. PLoS One. 2012. PMID: 23185547 Free PMC article.

• Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73.

  Liang H, Block TM, Wang M, Nefsky B, Long R, Hafner J, Mehta AS, Marrero J, Gish R, Norton PA. Liang H, et al. Cancer Biomark. 2012;11(4):161-71. doi: 10.3233/CBM-2012-00276. Cancer Biomark. 2012. PMID: 23144154 Free PMC article.

• Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice.

  Liu X, Zhang P, Martin RC, Cui G, Wang G, Tan Y, Cai L, Lv G, Li Y. Liu X, et al. Am J Cancer Res. 2016 May 1;6(5):1011-25. eCollection 2016. Am J Cancer Res. 2016. PMID: 27293995 Free PMC article.

• Potential antiproliferative and apoptotic effects of pilocarpine combined with TNF alpha in chronic myeloid leukemia cells.

  Kanlı Z, Cabadak H, Aydın B. Kanlı Z, et al. Naunyn Schmiedebergs Arch Pharmacol. 2023 Jul;396(7):1513-1524. doi: 10.1007/s00210-023-02418-4. Epub 2023 Feb 13. Naunyn Schmiedebergs Arch Pharmacol. 2023. PMID: 36781441

• Origin and role of hepatic myofibroblasts in hepatocellular carcinoma.

  Yavuz BG, Pestana RC, Abugabal YI, Krishnan S, Chen J, Hassan MM, Wolff RA, Rashid A, Amin HM, Kaseb AO. Yavuz BG, et al. Oncotarget. 2020 Mar 31;11(13):1186-1201. doi: 10.18632/oncotarget.27532. eCollection 2020 Mar 31. Oncotarget. 2020. PMID: 32284794 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information